Matiz-I Granules is a combination pharmaceutical formulation containing Mebeverine 135 mg and Ispaghula 3.5 gm, indicated for the symptomatic relief of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders characterized by abdominal pain, bloating, and altered bowel habits. Mebeverine is an antispasmodic agent that acts directly on the smooth muscle of the gastrointestinal tract, alleviating muscle spasms without affecting normal gut motility, thereby reducing abdominal cramps and discomfort. Ispaghula, a bulk-forming laxative derived from the husk of Plantago ovata seeds, functions by absorbing water in the intestines, increasing stool bulk and promoting regular bowel movements, which aids in managing constipation and maintaining bowel health. The granule formulation allows for easy oral administration, typically dissolved in water before ingestion, facilitating patient compliance. Matiz-I Granules is generally well tolerated, with minimal adverse effects; however, patients should be advised to maintain adequate hydration when using Ispaghula to prevent potential intestinal obstruction. This combination therapy offers a dual mechanism approach targeting both smooth muscle spasm and bowel regulation, making it an effective option for comprehensive management of IBS symptoms. Use should be guided by a healthcare professional based on individual patient needs and clinical response.